Key facts
- Travere Therapeutics stock is rallying.
- Positive Phase 2 clinical trial data for pegtaralgene was announced.
- The trial evaluated pegtaralgene for IgA nephropathy.
Travere Therapeutics stock saw a significant rally today, driven by the release of positive clinical trial data. The company announced encouraging results from its Phase 2 study evaluating pegtaralgene as a treatment for IgA nephropathy. This positive development in its clinical pipeline is fueling investor confidence and driving the stock's upward movement.
